Neutrophil Gelatinase-Associated Lipocalin as a Marker of Disease Activity in Patients with Ulcerative Colitis Disease

• Published in: QJM : An International Journal of Medicine Vol. 116; no. Supplement_1
• Main Authors: El Rhman, Hany Ali Hessuin abd, Allam, Ahmed Samir, Raafat, Khaled Mohammed, El Ghany Ali, Maha Ezzat Abd
• Format: Journal Article
• Language: English
• Published: 23.08.2023
• ISSN: 1460-2725; 1460-2393
• DOI: 10.1093/qjmed/hcad069.439

Abstract Background Inflammatory bowel disease (IBD) is an idiopathic disease caused by a dysregulated immune response to host intestinal microflora. Although the etiology of IBD remains largely unknown, it involves a complex interaction between the genetic, environmental, or microbial factors and the immune responses. Aim of the Work This study will assess the the role of neutrophil gelatinase-associated lipocalin (NGAL) as a marker of disease activity in patients with Inflammatory bowel disease. Patients and Methods A cohort prospective study. The study conducted at Ain Shams University Hospitals. The study will take place from August 2020 to February 2021. Our study conducted on 60 Egyptian person over 18 years old visiting the outpatient clinics or admitted in Ain Shams University Hospitals. The study conducted on 40 Egyptian patients with inflammatory bowel disease. Results The present study revealed a highly significant elevation of serum NGAL in active IBD patients with p-value <0.001 which show direct relationship between the activity and severity of UC and CD disease and serum NGAL was positively correlated with inflammatory markers (CRP and ESR) in UC and CD patients. And there is negative relation between serum hemoglobin and NGAL. Conclusion Serum NGAL is a valuable noninvasive marker in the assessment of activity in IBD patients correlated positively with inflammatory markers (CRP and ESR) and markers of disease activity (UCAI and UC histopathology grading in UC patients and clinical CDAI in CD patients). Other studies should be done on larger size of participants to determine the the role of neutrophil gelatinase-associated lipocalin (NGAL) as a marker of disease activity in patients with Inflammatory bowel disease.